- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Neurodegenerative Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Neurodegenerative Drugs market size is estimated to be worth US$ 118360 million in 2021 and is forecast to a readjusted size of USD 174250 million by 2028 with a CAGR of 5.7% during review period. Parkinson’s Disease accounting for % of the Neurodegenerative Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While NMDA segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Neurodegenerative Drugs include Novartis, Pfizer, Merck Serono, Biogen Idec, and TEVA, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neurodegenerative Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
NMDA
SSRIs
Dopamine Inhibitors
Market segment by Application can be divided into
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
The key market players for global Neurodegenerative Drugs market are listed below:
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neurodegenerative Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neurodegenerative Drugs, with price, sales, revenue and global market share of Neurodegenerative Drugs from 2019 to 2022.
Chapter 3, the Neurodegenerative Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neurodegenerative Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neurodegenerative Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurodegenerative Drugs.
Chapter 13, 14, and 15, to describe Neurodegenerative Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Neurodegenerative Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neurodegenerative Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Market Analysis by Application
1.3.1 Overview: Global Neurodegenerative Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Global Neurodegenerative Drugs Market Size & Forecast
1.4.1 Global Neurodegenerative Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Neurodegenerative Drugs Sales in Volume (2017-2028)
1.4.3 Global Neurodegenerative Drugs Price (2017-2028)
1.5 Global Neurodegenerative Drugs Production Capacity Analysis
1.5.1 Global Neurodegenerative Drugs Total Production Capacity (2017-2028)
1.5.2 Global Neurodegenerative Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neurodegenerative Drugs Market Drivers
1.6.2 Neurodegenerative Drugs Market Restraints
1.6.3 Neurodegenerative Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Neurodegenerative Drugs Product and Services
2.1.4 Novartis Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Neurodegenerative Drugs Product and Services
2.2.4 Pfizer Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Merck Serono
2.3.1 Merck Serono Details
2.3.2 Merck Serono Major Business
2.3.3 Merck Serono Neurodegenerative Drugs Product and Services
2.3.4 Merck Serono Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Biogen Idec
2.4.1 Biogen Idec Details
2.4.2 Biogen Idec Major Business
2.4.3 Biogen Idec Neurodegenerative Drugs Product and Services
2.4.4 Biogen Idec Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 TEVA
2.5.1 TEVA Details
2.5.2 TEVA Major Business
2.5.3 TEVA Neurodegenerative Drugs Product and Services
2.5.4 TEVA Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 UCB
2.6.1 UCB Details
2.6.2 UCB Major Business
2.6.3 UCB Neurodegenerative Drugs Product and Services
2.6.4 UCB Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Boehringer Ingelheim
2.7.1 Boehringer Ingelheim Details
2.7.2 Boehringer Ingelheim Major Business
2.7.3 Boehringer Ingelheim Neurodegenerative Drugs Product and Services
2.7.4 Boehringer Ingelheim Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Neurodegenerative Drugs Product and Services
2.8.4 Sanofi Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 GlaxoSmithKline
2.9.1 GlaxoSmithKline Details
2.9.2 GlaxoSmithKline Major Business
2.9.3 GlaxoSmithKline Neurodegenerative Drugs Product and Services
2.9.4 GlaxoSmithKline Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Livzon Pharmaceutical
2.10.1 Livzon Pharmaceutical Details
2.10.2 Livzon Pharmaceutical Major Business
2.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Product and Services
2.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Haisco Pharmaceutical
2.11.1 Haisco Pharmaceutical Details
2.11.2 Haisco Pharmaceutical Major Business
2.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Product and Services
2.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Jingxin Pharmaceutical
2.12.1 Jingxin Pharmaceutical Details
2.12.2 Jingxin Pharmaceutical Major Business
2.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Product and Services
2.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Dongcheng Biochemicals
2.13.1 Dongcheng Biochemicals Details
2.13.2 Dongcheng Biochemicals Major Business
2.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Product and Services
2.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Hisun Pharmaceutical
2.14.1 Hisun Pharmaceutical Details
2.14.2 Hisun Pharmaceutical Major Business
2.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Product and Services
2.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Luye Pharma
2.15.1 Luye Pharma Details
2.15.2 Luye Pharma Major Business
2.15.3 Luye Pharma Neurodegenerative Drugs Product and Services
2.15.4 Luye Pharma Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 Ark Pharmaceutical
2.16.1 Ark Pharmaceutical Details
2.16.2 Ark Pharmaceutical Major Business
2.16.3 Ark Pharmaceutical Neurodegenerative Drugs Product and Services
2.16.4 Ark Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17 Kanghong Pharmaceutical
2.17.1 Kanghong Pharmaceutical Details
2.17.2 Kanghong Pharmaceutical Major Business
2.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Product and Services
2.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18 Huahai Pharmaceutical
2.18.1 Huahai Pharmaceutical Details
2.18.2 Huahai Pharmaceutical Major Business
2.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Product and Services
2.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19 BORA PHARMACEUTICALS
2.19.1 BORA PHARMACEUTICALS Details
2.19.2 BORA PHARMACEUTICALS Major Business
2.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Product and Services
2.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Neurodegenerative Drugs Breakdown Data by Manufacturer
3.1 Global Neurodegenerative Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Neurodegenerative Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Neurodegenerative Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Neurodegenerative Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Neurodegenerative Drugs Manufacturer Market Share in 2021
3.5 Global Neurodegenerative Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Neurodegenerative Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Neurodegenerative Drugs Market Size by Region
4.1.1 Global Neurodegenerative Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Neurodegenerative Drugs Revenue by Region (2017-2028)
4.2 North America Neurodegenerative Drugs Revenue (2017-2028)
4.3 Europe Neurodegenerative Drugs Revenue (2017-2028)
4.4 Asia-Pacific Neurodegenerative Drugs Revenue (2017-2028)
4.5 South America Neurodegenerative Drugs Revenue (2017-2028)
4.6 Middle East and Africa Neurodegenerative Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Neurodegenerative Drugs Sales in Volume by Type (2017-2028)
5.2 Global Neurodegenerative Drugs Revenue by Type (2017-2028)
5.3 Global Neurodegenerative Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Neurodegenerative Drugs Sales in Volume by Application (2017-2028)
6.2 Global Neurodegenerative Drugs Revenue by Application (2017-2028)
6.3 Global Neurodegenerative Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Neurodegenerative Drugs Sales by Type (2017-2028)
7.2 North America Neurodegenerative Drugs Sales by Application (2017-2028)
7.3 North America Neurodegenerative Drugs Market Size by Country
7.3.1 North America Neurodegenerative Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Neurodegenerative Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Neurodegenerative Drugs Sales by Type (2017-2028)
8.2 Europe Neurodegenerative Drugs Sales by Application (2017-2028)
8.3 Europe Neurodegenerative Drugs Market Size by Country
8.3.1 Europe Neurodegenerative Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Neurodegenerative Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Neurodegenerative Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Neurodegenerative Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Neurodegenerative Drugs Market Size by Region
9.3.1 Asia-Pacific Neurodegenerative Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Neurodegenerative Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Neurodegenerative Drugs Sales by Type (2017-2028)
10.2 South America Neurodegenerative Drugs Sales by Application (2017-2028)
10.3 South America Neurodegenerative Drugs Market Size by Country
10.3.1 South America Neurodegenerative Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Neurodegenerative Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Neurodegenerative Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Neurodegenerative Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Neurodegenerative Drugs Market Size by Country
11.3.1 Middle East & Africa Neurodegenerative Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Neurodegenerative Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Neurodegenerative Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Neurodegenerative Drugs
12.3 Neurodegenerative Drugs Production Process
12.4 Neurodegenerative Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Neurodegenerative Drugs Typical Distributors
13.3 Neurodegenerative Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Neurodegenerative Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Neurodegenerative Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Novartis Basic Information, Manufacturing Base and Competitors
Table 4. Novartis Major Business
Table 5. Novartis Neurodegenerative Drugs Product and Services
Table 6. Novartis Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Pfizer Basic Information, Manufacturing Base and Competitors
Table 8. Pfizer Major Business
Table 9. Pfizer Neurodegenerative Drugs Product and Services
Table 10. Pfizer Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Merck Serono Basic Information, Manufacturing Base and Competitors
Table 12. Merck Serono Major Business
Table 13. Merck Serono Neurodegenerative Drugs Product and Services
Table 14. Merck Serono Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Biogen Idec Basic Information, Manufacturing Base and Competitors
Table 16. Biogen Idec Major Business
Table 17. Biogen Idec Neurodegenerative Drugs Product and Services
Table 18. Biogen Idec Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. TEVA Basic Information, Manufacturing Base and Competitors
Table 20. TEVA Major Business
Table 21. TEVA Neurodegenerative Drugs Product and Services
Table 22. TEVA Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. UCB Basic Information, Manufacturing Base and Competitors
Table 24. UCB Major Business
Table 25. UCB Neurodegenerative Drugs Product and Services
Table 26. UCB Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 28. Boehringer Ingelheim Major Business
Table 29. Boehringer Ingelheim Neurodegenerative Drugs Product and Services
Table 30. Boehringer Ingelheim Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Sanofi Basic Information, Manufacturing Base and Competitors
Table 32. Sanofi Major Business
Table 33. Sanofi Neurodegenerative Drugs Product and Services
Table 34. Sanofi Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 36. GlaxoSmithKline Major Business
Table 37. GlaxoSmithKline Neurodegenerative Drugs Product and Services
Table 38. GlaxoSmithKline Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Livzon Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 40. Livzon Pharmaceutical Major Business
Table 41. Livzon Pharmaceutical Neurodegenerative Drugs Product and Services
Table 42. Livzon Pharmaceutical Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Haisco Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 44. Haisco Pharmaceutical Major Business
Table 45. Haisco Pharmaceutical Neurodegenerative Drugs Product and Services
Table 46. Haisco Pharmaceutical Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Jingxin Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 48. Jingxin Pharmaceutical Major Business
Table 49. Jingxin Pharmaceutical Neurodegenerative Drugs Product and Services
Table 50. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Dongcheng Biochemicals Basic Information, Manufacturing Base and Competitors
Table 52. Dongcheng Biochemicals Major Business
Table 53. Dongcheng Biochemicals Neurodegenerative Drugs Product and Services
Table 54. Dongcheng Biochemicals Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Hisun Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 56. Hisun Pharmaceutical Major Business
Table 57. Hisun Pharmaceutical Neurodegenerative Drugs Product and Services
Table 58. Hisun Pharmaceutical Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 59. Luye Pharma Basic Information, Manufacturing Base and Competitors
Table 60. Luye Pharma Major Business
Table 61. Luye Pharma Neurodegenerative Drugs Product and Services
Table 62. Luye Pharma Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 63. Ark Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 64. Ark Pharmaceutical Major Business
Table 65. Ark Pharmaceutical Neurodegenerative Drugs Product and Services
Table 66. Ark Pharmaceutical Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 67. Kanghong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 68. Kanghong Pharmaceutical Major Business
Table 69. Kanghong Pharmaceutical Neurodegenerative Drugs Product and Services
Table 70. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 71. Huahai Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 72. Huahai Pharmaceutical Major Business
Table 73. Huahai Pharmaceutical Neurodegenerative Drugs Product and Services
Table 74. Huahai Pharmaceutical Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 75. BORA PHARMACEUTICALS Basic Information, Manufacturing Base and Competitors
Table 76. BORA PHARMACEUTICALS Major Business
Table 77. BORA PHARMACEUTICALS Neurodegenerative Drugs Product and Services
Table 78. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 79. Global Neurodegenerative Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 80. Global Neurodegenerative Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 81. Market Position of Manufacturers in Neurodegenerative Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 82. Global Neurodegenerative Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 83. Head Office and Neurodegenerative Drugs Production Site of Key Manufacturer
Table 84. Neurodegenerative Drugs New Entrant and Capacity Expansion Plans
Table 85. Neurodegenerative Drugs Mergers & Acquisitions in the Past Five Years
Table 86. Global Neurodegenerative Drugs Sales by Region (2017-2022) & (K Units)
Table 87. Global Neurodegenerative Drugs Sales by Region (2023-2028) & (K Units)
Table 88. Global Neurodegenerative Drugs Revenue by Region (2017-2022) & (USD Million)
Table 89. Global Neurodegenerative Drugs Revenue by Region (2023-2028) & (USD Million)
Table 90. Global Neurodegenerative Drugs Sales by Type (2017-2022) & (K Units)
Table 91. Global Neurodegenerative Drugs Sales by Type (2023-2028) & (K Units)
Table 92. Global Neurodegenerative Drugs Revenue by Type (2017-2022) & (USD Million)
Table 93. Global Neurodegenerative Drugs Revenue by Type (2023-2028) & (USD Million)
Table 94. Global Neurodegenerative Drugs Price by Type (2017-2022) & (US$/Unit)
Table 95. Global Neurodegenerative Drugs Price by Type (2023-2028) & (US$/Unit)
Table 96. Global Neurodegenerative Drugs Sales by Application (2017-2022) & (K Units)
Table 97. Global Neurodegenerative Drugs Sales by Application (2023-2028) & (K Units)
Table 98. Global Neurodegenerative Drugs Revenue by Application (2017-2022) & (USD Million)
Table 99. Global Neurodegenerative Drugs Revenue by Application (2023-2028) & (USD Million)
Table 100. Global Neurodegenerative Drugs Price by Application (2017-2022) & (US$/Unit)
Table 101. Global Neurodegenerative Drugs Price by Application (2023-2028) & (US$/Unit)
Table 102. North America Neurodegenerative Drugs Sales by Country (2017-2022) & (K Units)
Table 103. North America Neurodegenerative Drugs Sales by Country (2023-2028) & (K Units)
Table 104. North America Neurodegenerative Drugs Revenue by Country (2017-2022) & (USD Million)
Table 105. North America Neurodegenerative Drugs Revenue by Country (2023-2028) & (USD Million)
Table 106. North America Neurodegenerative Drugs Sales by Type (2017-2022) & (K Units)
Table 107. North America Neurodegenerative Drugs Sales by Type (2023-2028) & (K Units)
Table 108. North America Neurodegenerative Drugs Sales by Application (2017-2022) & (K Units)
Table 109. North America Neurodegenerative Drugs Sales by Application (2023-2028) & (K Units)
Table 110. Europe Neurodegenerative Drugs Sales by Country (2017-2022) & (K Units)
Table 111. Europe Neurodegenerative Drugs Sales by Country (2023-2028) & (K Units)
Table 112. Europe Neurodegenerative Drugs Revenue by Country (2017-2022) & (USD Million)
Table 113. Europe Neurodegenerative Drugs Revenue by Country (2023-2028) & (USD Million)
Table 114. Europe Neurodegenerative Drugs Sales by Type (2017-2022) & (K Units)
Table 115. Europe Neurodegenerative Drugs Sales by Type (2023-2028) & (K Units)
Table 116. Europe Neurodegenerative Drugs Sales by Application (2017-2022) & (K Units)
Table 117. Europe Neurodegenerative Drugs Sales by Application (2023-2028) & (K Units)
Table 118. Asia-Pacific Neurodegenerative Drugs Sales by Region (2017-2022) & (K Units)
Table 119. Asia-Pacific Neurodegenerative Drugs Sales by Region (2023-2028) & (K Units)
Table 120. Asia-Pacific Neurodegenerative Drugs Revenue by Region (2017-2022) & (USD Million)
Table 121. Asia-Pacific Neurodegenerative Drugs Revenue by Region (2023-2028) & (USD Million)
Table 122. Asia-Pacific Neurodegenerative Drugs Sales by Type (2017-2022) & (K Units)
Table 123. Asia-Pacific Neurodegenerative Drugs Sales by Type (2023-2028) & (K Units)
Table 124. Asia-Pacific Neurodegenerative Drugs Sales by Application (2017-2022) & (K Units)
Table 125. Asia-Pacific Neurodegenerative Drugs Sales by Application (2023-2028) & (K Units)
Table 126. South America Neurodegenerative Drugs Sales by Country (2017-2022) & (K Units)
Table 127. South America Neurodegenerative Drugs Sales by Country (2023-2028) & (K Units)
Table 128. South America Neurodegenerative Drugs Revenue by Country (2017-2022) & (USD Million)
Table 129. South America Neurodegenerative Drugs Revenue by Country (2023-2028) & (USD Million)
Table 130. South America Neurodegenerative Drugs Sales by Type (2017-2022) & (K Units)
Table 131. South America Neurodegenerative Drugs Sales by Type (2023-2028) & (K Units)
Table 132. South America Neurodegenerative Drugs Sales by Application (2017-2022) & (K Units)
Table 133. South America Neurodegenerative Drugs Sales by Application (2023-2028) & (K Units)
Table 134. Middle East & Africa Neurodegenerative Drugs Sales by Region (2017-2022) & (K Units)
Table 135. Middle East & Africa Neurodegenerative Drugs Sales by Region (2023-2028) & (K Units)
Table 136. Middle East & Africa Neurodegenerative Drugs Revenue by Region (2017-2022) & (USD Million)
Table 137. Middle East & Africa Neurodegenerative Drugs Revenue by Region (2023-2028) & (USD Million)
Table 138. Middle East & Africa Neurodegenerative Drugs Sales by Type (2017-2022) & (K Units)
Table 139. Middle East & Africa Neurodegenerative Drugs Sales by Type (2023-2028) & (K Units)
Table 140. Middle East & Africa Neurodegenerative Drugs Sales by Application (2017-2022) & (K Units)
Table 141. Middle East & Africa Neurodegenerative Drugs Sales by Application (2023-2028) & (K Units)
Table 142. Neurodegenerative Drugs Raw Material
Table 143. Key Manufacturers of Neurodegenerative Drugs Raw Materials
Table 144. Direct Channel Pros & Cons
Table 145. Indirect Channel Pros & Cons
Table 146. Neurodegenerative Drugs Typical Distributors
Table 147. Neurodegenerative Drugs Typical Customers
List of Figures
Figure 1. Neurodegenerative Drugs Picture
Figure 2. Global Neurodegenerative Drugs Revenue Market Share by Type in 2021
Figure 3. NMDA
Figure 4. SSRIs
Figure 5. Dopamine Inhibitors
Figure 6. Global Neurodegenerative Drugs Revenue Market Share by Application in 2021
Figure 7. Parkinson’s Disease
Figure 8. Huntington Disease
Figure 9. Amyotrophic Lateral Sclerosis
Figure 10. Alzheimer’s Disease
Figure 11. Global Neurodegenerative Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 12. Global Neurodegenerative Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Neurodegenerative Drugs Sales (2017-2028) & (K Units)
Figure 14. Global Neurodegenerative Drugs Price (2017-2028) & (US$/Unit)
Figure 15. Global Neurodegenerative Drugs Production Capacity (2017-2028) & (K Units)
Figure 16. Global Neurodegenerative Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 17. Neurodegenerative Drugs Market Drivers
Figure 18. Neurodegenerative Drugs Market Restraints
Figure 19. Neurodegenerative Drugs Market Trends
Figure 20. Global Neurodegenerative Drugs Sales Market Share by Manufacturer in 2021
Figure 21. Global Neurodegenerative Drugs Revenue Market Share by Manufacturer in 2021
Figure 22. Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 23. Top 3 Neurodegenerative Drugs Manufacturer (Revenue) Market Share in 2021
Figure 24. Top 6 Neurodegenerative Drugs Manufacturer (Revenue) Market Share in 2021
Figure 25. Global Neurodegenerative Drugs Sales Market Share by Region (2017-2028)
Figure 26. Global Neurodegenerative Drugs Revenue Market Share by Region (2017-2028)
Figure 27. North America Neurodegenerative Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Europe Neurodegenerative Drugs Revenue (2017-2028) & (USD Million)
Figure 29. Asia-Pacific Neurodegenerative Drugs Revenue (2017-2028) & (USD Million)
Figure 30. South America Neurodegenerative Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Middle East & Africa Neurodegenerative Drugs Revenue (2017-2028) & (USD Million)
Figure 32. Global Neurodegenerative Drugs Sales Market Share by Type (2017-2028)
Figure 33. Global Neurodegenerative Drugs Revenue Market Share by Type (2017-2028)
Figure 34. Global Neurodegenerative Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 35. Global Neurodegenerative Drugs Sales Market Share by Application (2017-2028)
Figure 36. Global Neurodegenerative Drugs Revenue Market Share by Application (2017-2028)
Figure 37. Global Neurodegenerative Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 38. North America Neurodegenerative Drugs Sales Market Share by Type (2017-2028)
Figure 39. North America Neurodegenerative Drugs Sales Market Share by Application (2017-2028)
Figure 40. North America Neurodegenerative Drugs Sales Market Share by Country (2017-2028)
Figure 41. North America Neurodegenerative Drugs Revenue Market Share by Country (2017-2028)
Figure 42. United States Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Canada Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Mexico Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Europe Neurodegenerative Drugs Sales Market Share by Type (2017-2028)
Figure 46. Europe Neurodegenerative Drugs Sales Market Share by Application (2017-2028)
Figure 47. Europe Neurodegenerative Drugs Sales Market Share by Country (2017-2028)
Figure 48. Europe Neurodegenerative Drugs Revenue Market Share by Country (2017-2028)
Figure 49. Germany Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. France Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. United Kingdom Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Russia Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Italy Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Asia-Pacific Neurodegenerative Drugs Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Neurodegenerative Drugs Sales Market Share by Application (2017-2028)
Figure 56. Asia-Pacific Neurodegenerative Drugs Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Neurodegenerative Drugs Revenue Market Share by Region (2017-2028)
Figure 58. China Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Korea Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Neurodegenerative Drugs Sales Market Share by Type (2017-2028)
Figure 65. South America Neurodegenerative Drugs Sales Market Share by Application (2017-2028)
Figure 66. South America Neurodegenerative Drugs Sales Market Share by Country (2017-2028)
Figure 67. South America Neurodegenerative Drugs Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Type (2017-2028)
Figure 71. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Application (2017-2028)
Figure 72. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Region (2017-2028)
Figure 73. Middle East & Africa Neurodegenerative Drugs Revenue Market Share by Region (2017-2028)
Figure 74. Turkey Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Egypt Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. South Africa Neurodegenerative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Manufacturing Cost Structure Analysis of Neurodegenerative Drugs in 2021
Figure 79. Manufacturing Process Analysis of Neurodegenerative Drugs
Figure 80. Neurodegenerative Drugs Industrial Chain
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
